Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
600 participants
OBSERVATIONAL
2021-11-18
2027-09-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adult Spinal Muscular Atrophy (SMA) China Registry
NCT05618379
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
NCT05824169
A Registered Cohort Study on SMA
NCT04010604
European Registry of Patients With Infantile-onset Spinal Muscular Atrophy
NCT03339830
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DMT Treated Participants
Participants with SMA who received prior treatment with DMTs including nusinersen will be followed prospectively for up to 60 months and the available data is collected retrospectively.
No interventions assigned to this group
Untreated Participants
Participants with SMA who received no treatment will be followed prospectively for up to 60 months.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Genetically confirmed 5q-SMA.
* Age \< 18 years at enrollment.
Exclusion Criteria
* Other types of SMA (non 5q-SMA).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Children's Hospital
Hefei, Anhui, China
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Children's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
Xiamen Maternal and Child Health Hospital
Xiamen, Fujian, China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Shenzhen Children's Hospital
Shenzhen, Guangdong, China
Maternity and Child Health Care of Guangxi Zhuang Autonomous Region
Nanning, Guangxi Zhuang, China
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
The Third Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Children's Hospital
Changsha, Hu'nan, China
Xiangya Hospital, Central South University
Changsha, Hu'nan, China
Wuhan Children's Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, Hubei, China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, Inner Mongolia, China
Xuzhou Central Hospital
Xuzhou, Jiangsu, China
Jiangxi Provincial Children's Hospital
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Children's Hospital Affiliated to Shandong University
Jinan, Jinan Shandong, China
Dalian Women and Children's Medical Group
Dalian, Liaoning, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
People's Hospital of Ningxia Hui Autonomous Region
Yinchuan, Ningxia Hui, China
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital of Xi'An Jiaotong University
Xi’an, Shanxi, China
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CN-SMG-11774
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.